Atosiban Combined with Ritodrine for Late Threatened Abortion or Threatened Premature Labor Patients with No Response to Ritodrine: A Clinical Trial

Shuai Fu; Haitian Xie; Yilei Zhong; Qi Xu; Liqiong Zhu; Hanjie Mo; Jianping Zhang; Yinglin Liu; Hui Chen; Yonghong Zhong; Jianping Tan

doi:10.12659/MSM.929743

18 March 2021 : Clinical Research

Atosiban Combined with Ritodrine for Late Threatened Abortion or Threatened Premature Labor Patients with No Response to Ritodrine: A Clinical Trial

Shuai Fu^1ABC, Haitian Xie^1DEF, Yilei Zhong^12BCD, Qi Xu^1D, Liqiong Zhu^1B, Hanjie Mo^1B, Jianping Zhang^1AG, Yinglin Liu^1CF, Hui Chen^1AG, Yonghong Zhong^2AD*, Jianping Tan^1AD

DOI: 10.12659/MSM.929743

Med Sci Monit 2021; 27:e929743

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 4 Dosage and pregnancy outcomes. Categorical data are shown as a frequency (percentage) and continuous data are shown as mean±SD. The t test was used for analyzing quantitative data, while the χ2 test was used for analyzing categorical data. P<0.05 was considered statistically significant.

Items	Control group (n=22)	Research group (n=30)	P
Extension of gestation (days)	93.55±42.29	42.53±31.70	<0.001^*
Mean infusion rate of ritodrine (drops/min)	6.68±2.46	6.67±1.92	0.980
Fetal loss rate (%)	13.64 (3/22)	26.67 (8/30)	0.257
Newborn birth weight (kg)	2.47±0.98	1.95±0.94	0.063
Apgar score at 1 minute	8.70±1.53	8.36±2.08	0.560
^*

Back to the Article

Atosiban Combined with Ritodrine for Late Threatened Abortion or Threatened Premature Labor Patients with No Response to Ritodrine: A Clinical Trial

Your Privacy